Sciwind Biosciences partners with Pfizer China on ecnoglutide. Explore what this GLP-1 deal changes for obesity, diabetes, and China’s drug market.
ViiV Healthcare heads to CROI 2026 with ultra long-acting HIV data for VH4524184, VH4011499 and more. See what it changes next.
Pfizer reports positive BREAKWATER data for BRAFTOVI in BRAF-mutant mCRC. Find out what this could change for frontline colorectal cancer care.
Explore what global spondyloarthritis trial trends in 2025 reveal about innovation gaps, sponsor risk, and regulatory hurdles. Read the full industry analysis.
Astellas Pharma Inc. and Pfizer Inc. have announced that their antibody-drug conjugate PADCEV (enfortumab vedotin), in combination with the PD-1 inhibitor pembrolizumab (marketed as Keytruda by Merck), met key survival endpoints in the Phase 3 EV-304 trial. In cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), the combination significantly improved both event-free survival and overall survival […]